This is the first time Dr Nagasawa, together with his son Scott Nagasawa had publicly shared the challenges they faced while remaining dedicated to solving a serious problem. Although he and his team faced numerous setbacks before this incredible breakthrough, they never gave up. And it’s the story behind that dedication that we wanted to share with you today.
If you’re not a medical professional, although you might struggle with understanding the scientific research below, it’s still worth reading. It will give you some amazing insight into why Dr Nagasawa remained so dedicated to Riboceine research.
How did alcohol abuse play a part in the development of Riboceine?
Dr Nagasawa opened the presentation by talking about the terrible drug and alcohol addictions veterans were left with, after returning home from the Vietnam War. And how sadly, given the unpopularity of the War, returning soldiers didn’t receive a warm welcome and were mostly frowned upon or shunned by society. One of the returning veteran’s who suffered this fate, was Dr Nagasawa’s own brother. The popular 80′s movie Born on the 4th of July gave an excellent portrayal of the controversy these soldiers faced.
In response to the high percentage of veterans returning home with debilitating alcohol addictions, the Veteran’s Administration realized they needed more effective drugs than Antabuse, to prevent alcoholism. They decided they needed new drugs that could prevent or protect alcoholic’s from developing fatty livers, which leads to Cirrhosis, eventually a liver transplant, or death.
Dr. Nagasawa then went into detail about how alcohol is metabolized in the body. The challenge he faced was, was it possible to interrupt the metabolizing process of alcohol by trapping acetaldehyde (AcH) and diverting the product to urinary excretion?
Through numerous initial research studies, Dr Nagasawa’s research team discovered that the MTCA compound, provided an effective means of delivering cysteine. Given alcoholics are known to have lower levels of glutathione, they reasoned that using MTCA as a bioavailable delivery system for cysteine could stimulate the body’s development of glutathione and protect the liver from the oxidative stress of chronic alcoholism.
“A medical student volunteered to test this theory through a preliminary experiment”
Because liver damage from consuming alcohol can take a substantial amount of time to develop, they chose to test on a similar liver problem. An overdose of Acetaminophen, (the active pain reliever in many over the counter headache/cold and flu medicines), produces liver and kidney damage similar to the effects of cirrhosis.
The results were very promising, as they showed that L-MTCA could have very similar results to NAC, the current “gold standard” for treating ACP overdose. From this experiment the team applied for a grant for further testing. However, a major critique of the grant proposal was that, while MTCA protects against hepatotoxicity, it also delivers the toxic compound acetaldehyde. Though that amount was very minuscule, the grant was denied.
Appreciating this denial as part of the rigorous nature of peer review, Dr. Nagasawa knew he had to keep an open mind while moving forward.
The team knew they needed compounds that were non-toxic to combine with cysteine in order to effectively deliver it to the cell. They realized that we do have such compounds in our own body, namely aldose monosaccharide, or the simple sugars produced when glucose is metabolized.
To test this possibility, grad student Jeanette Roberts prepared the sugar-cysteine condensation produced from 8 different aldose saccharides. The next experiment showed that livers that had an overdose of ACP plus the saccharide D-ribose combined with cysteine had 100% survival rate from the in vivo experiments, while the next best compound, glucose-cysteine did not perform nearly as well.
Jackpot! Ribose-Cysteine protected the liver from a toxic dose of ACP. Ribose-Cysteine serves as an effective delivery method of bringing L-cysteine to cells, simulate glutathione biosynthesis and protecting them from toxins. The ribose-cysteine compound also makes for an ideal dietary supplement since it’s made from endogenous elements already in our body.
“Dr Nagasawa first published about Riboceine in 1987″
Later experiments also revealed that ribose-cysteine, was even more effective than N-Acetyl Cysteine in raising glutathione within a liver cell.
The presentation concluded with closing thoughts on Cellgevity.
After conducting numerous experiments, Dr Nagasawa and his research team know, that thanks to the technology behind Riboceine, Cellgevity is in a category of it’s own. Riboceine solves the problem of being able to effectively deliver cysteine to the cell.
Watch the Riboceine video on Youtube!
Dr Nagasawa’s philosophy in science is, “it’s important to keep an open mind.” His extraordinary ability to think outside the box, is what’s enabled he and his research team, to bring Riboceine to the world.
Now it’s your chance to help Dr Nagasawa spread the word on Riboceine by clicking the ‘like’ button below.
*These statements have not been evaluated by the Food and Drug Administration. Please seek advice from a qualified medical professional before beginning any nutritional program. Riboceine products are not intended to diagnose, treat, cure or prevent any disease.